Clinical trial · no report yet · Phase 3
DeLLphi-305
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
- NCT06211036 ↗
- Active not recruiting
- Amgen
- 74 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 29 | |
| YouTube | 28 | |
| Podcasts | 17 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer
- Interventions
- Tarlatamab; Durvalumab
- Arms
- Tarlatamab in Combination With Durvalumab · Experimental
- Durvalumab Alone · Active comparator
- Enrollment
- 563
- Primary outcomes
- OS
- Sponsor
- Amgen
- Start
- Jun 5, 2024
- Primary completion
- Jul 5, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06211036 · updated Dec 17, 2025
Publications
linked from the registry- Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8. PubMed 40934933